



Have you noticed?

Women >35 years often experience higher dropout rates¹⁻⁴ and face longer time-to-pregnancy⁵⁻⁷

1. Kreuzer et al 2019; 2. Messaoud et al 2023; 3. De Naubourg et al 2021; 4. Bedrick et al 2019; 5. Delbaere et al 2020; 6. Magnus et al 2019; 7. Molina Garcia et al 2019

©2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.
Fictional patients. For illustrative purposes only

GL-PER-00327 June 2025




Age-related functional LH/FSH deficiency can be further exacerbated by standard downregulation protocols¹⁻⁴



When > **35**
years old, every
cycle counts



Optimize outcomes from 1st cycle^{1-8*} with Pergoveris®



*Pergoveris® is indicated for adult women with severe FSH and LH deficiency.
Other strengths of Pergoveris® pen are available: Pergoveris® Pen 300 IU r-hFSH/150 IU r-hLH, Pergoveris® Pen 450 IU r-hFSH/225 IU r-hLH, depending of the status of registration in the country.

1. PERGOVERIS® EU product information, Jun 2025; 2. Bielefeld et al., 2024; 3. Conforti et al 2021; 4. Kol S et al 2014; 5. Tayyar, et al. 2019; 6. Ferraretti et al., 2004; 7. Setti et al 2021; 8. Chen et al 2022;

©2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.
Fictional patients. For illustrative purposes only



GL-PER-00327 June 2025

Full and abbreviated product information is readily available on the booth.
Scan the QR code for Pergoveris® SmPC

This material is intended for an international audience of qualified healthcare professionals and is based on the Pergoveris® Summary of Product Characteristics (SmPC) approved for use in the European Economic Area (EEA). SmPC/Prescribing information may vary depending on local approval in each country. Therefore, before prescribing Pergoveris®, always refer to local official documents such as SmPC and/or prescribing information. For the SmPC approved for use in the EEA, please access: <https://www.ema.europa.eu>